There are at least a dozen compounds sold as weight loss peptides. They are not equivalent. Some have Phase 3 trials with tens of thousands of participants and FDA approvals. Others have a single mouse study and a vendor marketing page. This post ranks every weight loss compound in our database by the strength of its human evidence, from strongest to weakest.
This is not a ranking of popularity, vendor availability, or social media mentions. It is a ranking of published clinical data in humans. If a compound has never been tested in a human weight loss trial, it belongs at the bottom of the hierarchy regardless of how many influencers recommend it.
Semaglutide (Wegovy): STEP-1 (n=1,961): 14.9% weight loss at 68 weeks. SELECT (n=17,604): 20% MACE reduction. FLOW (n=3,534): 24% kidney event reduction. ESSENCE: 62.9% MASH resolution. Oral Wegovy approved December 2025. The most extensively validated weight loss compound in existence.
Tirzepatide (Zepbound): SURMOUNT-1 (n=2,539): 20.9% weight loss at 72 weeks. 3-year data: 22.9% sustained. SURMOUNT-5 head-to-head: 47% greater weight loss than semaglutide. First drug ever approved for obstructive sleep apnea. 94% diabetes prevention in prediabetes (NNT 9).
Retatrutide (Eli Lilly): Triple GIP/GLP-1/glucagon agonist. Phase 2 (n=338): 24.2% weight loss at 48 weeks. TRIUMPH-4 Phase 3 (n=445): 28.7% at 68 weeks, all endpoints met. Seven additional Phase 3 readouts expected in 2026. Not yet approved or available outside clinical trials.
CJC-1295 + Ipamorelin: The most prescribed GH secretagogue stack in biohacking. Both compounds confirmed GH stimulation in humans. Neither has demonstrated weight loss efficacy in a controlled trial. No published human trial has tested the combination. Read the full CJC-1295 profile and ipamorelin profile.
MK-677 (Ibutamoren): Oral GH secretagogue. Increases GH and IGF-1 reliably. Multiple human trials show increased appetite and modest fat-free mass gains, but no net weight loss. MK-677 typically increases body weight due to appetite stimulation and water retention.
AOD-9604: Six human trials, approximately 900 participants. Phase IIa showed 2.6 to 2.8 kg weight loss at 12 weeks. Phase IIb OPTIONS trial (n=536, 24 weeks): primary endpoint failed at every dose. Development terminated 2007. Cannot be legally compounded in the United States.
5-Amino-1MQ: NNMT inhibitor, not a peptide. Mouse data shows fat mass reduction without food intake changes (Neelakantan 2018, Babula 2024). No human clinical trial has been published. Entirely preclinical.
GH Fragment 176-191: Unmodified hGH C-terminal fragment (AOD-9604 without the stabilizing tyrosine). Preclinical lipolysis data only. No human weight loss trial. Less stable than AOD-9604, which itself failed in humans.
The compounds with the strongest evidence are fully approved pharmaceuticals developed by Novo Nordisk and Eli Lilly with billion-dollar Phase 3 programs. The compounds most commonly discussed in biohacking forums are clustered at the bottom of the hierarchy with minimal or failed human data.
This is not a coincidence. Vendor marketing is inversely correlated with evidence quality. The compounds that need marketing the most are the ones with the least data to speak for them. The compounds with the best data are prescribed by physicians and covered by insurance.
The weight loss peptide hierarchy is not a spectrum of roughly equivalent options. It is a cliff. Semaglutide, tirzepatide, and retatrutide sit at the top with Phase 3 data enrolling thousands of participants. Everything else in the peptide vendor catalog sits at the bottom with either failed trials, preclinical data only, or no human evidence at all. Knowing where a compound falls on this hierarchy is the minimum standard for making an informed decision.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use